Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339062 · ClinicalTrials.gov registry record · Phase 1
Cemiplimab in AlloSCT/SOT Recipients With CSCC
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04339062 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants.
The verdict
NCT04339062, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney transplant. \- This research study involves the following drug(s): * Cemiplimab * Everolimus or Sirolimus * Prednisone
Interventions
- DRUG Sirolimus
- DRUG Cemiplimab
- DRUG Everolimus
- DRUG Prednisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-11-03 |
| Est. Completion | 2025-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04339062
The ClinicalTrials.gov registry entry for NCT04339062 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sirolimus is the first listed.
NCT04339062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04339062 about?
NCT04339062 is a clinical study titled "Cemiplimab in AlloSCT/SOT Recipients With CSCC". In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney transplant. \- This research study involves the following drug(s): * Cemiplima...
What is the current status of trial NCT04339062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-11-03. Estimated completion is 2025-03-01.
What interventions are being tested in trial NCT04339062?
The interventions under investigation include: Sirolimus (DRUG), Cemiplimab (DRUG), Everolimus (DRUG), Prednisone (DRUG).
Who is sponsoring clinical trial NCT04339062?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.